

April 30, 2026

<p>To</p> <p><b>The Corporate Relations Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p><b>Code: 540222</b></p>	<p>To</p> <p><b>The Listing Department</b> <b>National Stock Exchange of India Ltd.,</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p><b>Code: LAURUSLABS</b></p>
--	--

Dear Sir / Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

We would like to inform that the Board of Directors of the Company at their meeting held on April 30, 2026, has *inter alia* transacted and approved the following businesses:

**(1) Appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454), as an Independent Director of the Company**

On the recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved and recommended to the shareholders of the Company for their approval for the appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454), as an Independent Director for a term of five (5) consecutive years with effect from July 02, 2026.

Dr. Shekhar Chintamani Mande is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in **Annexure-A**.

**(2) Appointment of Ms. Sutapa Banerjee (DIN: 02844650), as an Independent Director of the Company**

On the recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved and recommended to the shareholders of the Company for their approval for the appointment of Ms. Sutapa Banerjee (DIN: 02844650), as an Independent Director for a term of five (5) consecutive years with effect from July 02, 2026.

Ms. Sutapa Banerjee is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in **Annexure-A**.

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

CIN : L24239AP2005PLC047518

**(3) Retirement of Mrs. Aruna Bhinge (DIN: 07474950), as an Independent Director of the Company**

The Board took note of the retirement of Mrs. Aruna Bhinge (DIN: 07474950) as an Independent Director of the Company, with effect from close of business hours on July 6, 2026 after completion of her second term as an Independent Director which was from July 7, 2021 to July 6, 2026.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in **Annexure-A**.

**(4) Investment in KRKA Pharma Private Limited, a joint venture of the Company**

Approved the Investment of an amount up to INR equivalent of EURO 9,800,000/- (Euro Nine Million Eight Hundred Thousand only) in KRKA Pharma Private Limited, a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of INR equivalent of about EURO 10,200,000/- (Euro Ten Million and Two Hundred Thousand only) in KRKA. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited, respectively, shall continue to remain the same after the above investment.

This additional investment in KRKA aligns with the Company's strategic growth plans and long-term business objectives, and the fund will be utilised by KRKA to meet its capex plan for setting up of a manufacturing facility.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in **Annexure-B**.

**(5) Voluntary closure of step-down wholly owned subsidiary – Laurus Generics GmbH (Germany):**

Approved for the voluntary closure of Laurus Generics GmbH (Germany), a step-down wholly owned subsidiary in accordance with the applicable laws in Germany. Upon completion of closure formalities and regulatory approvals, Laurus Generics GmbH will cease to be a step-down subsidiary of the Company.

Further, Laurus Generics GmbH is not a material subsidiary of the Company. For the year March 31, 2026, the turnover of Laurus Generics GmbH was Nil. It may also be noted that the closure of Laurus Generics GmbH will not have any material impact on the Company or its financials.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in **Annexure-C**.

The Board Meeting commenced at 02.00 p.m. and concluded at 03.00 p.m.

This is for your information and records.

Thanking you,

Yours sincerely,  
For **Laurus Labs Limited**

**G. Venkateswar Reddy**  
**Company Secretary & Compliance Officer**

Encl: A/a

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

**CIN** : L24239AP2005PLC047518

**Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
(Pursuant to SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)

**Appointment and retirement of Independent Directors**

	<b>Name of the Director</b>	<b>Dr. Shekhar Chintamani Mande</b>	<b>Ms. Sutapa Banerjee</b>	<b>Mrs. Aruna Bhinge</b>
a	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454) as an Independent Director of the Company, subject to approval of the shareholders of the Company.	Appointment of Ms. Sutapa Banerjee (DIN: 02844650) as an Independent Director of the Company, subject to approval of the shareholders of the Company.	Retirement of Mrs. Aruna Bhinge (DIN: 07474950) as an Independent Director of the Company, with effect from close of business hours on July 6, 2026.
b	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/ re-appointment	Appointment is effective from July 02, 2025, for a tenure of 5 years.	Appointment is effective from July 02, 2025, for a tenure of 5 years.	Retirement will be effective from close of business hours on July 6, 2026 after completion of her second term as an Independent Director.
c	Brief Profile (in case of appointment)	Brief profile is annexed.	Brief profile is annexed.	Not applicable
d	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Shekhar Chintamani Mande is not related to any Director or Key Managerial Personnel of the Company	Ms. Sutapa Banerjee is not related to any Director or Key Managerial Personnel of the Company	Not applicable

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

**CIN** : L24239AP2005PLC047518

### **Brief profile of Dr. Shekhar Chintamani Mande**



Dr. Shekhar Chintamani Mande is a structural and computational biologist and a well-known research scientist. He is a distinguished professor at the Savitribai Phule Pune University, Pune. Prior to this, Dr. Mande was the Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), Government of India. He is one of India's leading experts in DNA fingerprinting and diagnostics. As Director of the National Centre for Cell Science (NCCS), an autonomous Institute of the Department of Biotechnology, Government of India, Dr. Mande oversaw the launch of the Indian Human Microbiome Initiative in the Northeast. In 2005, he was awarded the Shanti Swarup Bhatnagar Prize for Science and Technology – the most prestigious science award in India – in the category of Biological Sciences.

Currently, he serves as an Independent Director on the board of Tata Steel Limited and holds positions in various other organisations.

Dr. Mande holds a Ph.D. from Indian Institute of Science, Bangalore in Molecular Biophysics. He holds Masters and Bachelor's degree in physics from Nagpur University.

### **Brief profile of Ms. Sutapa Banerjee**



Ms. Sutapa Banerjee has over three decades of professional experience. She spent 24 years in the financial services industry across 2 large multinational banks (ANZ Grindlays and ABN AMRO), and a boutique Indian Investment bank (Ambit).

A well-recognized thought leader in the Wealth Management space, Ms. Sutapa was voted one of the 'Top 20 Global Rising Stars of Wealth Management' by the Institutional Investor Group in 2007 - the only Indian and one of only two winners from Asia. As CEO she led Ambit Private Wealth to 'Best Private Bank in India in the 2013 Asiamoney polls. In 2012, she was shortlisted in the '50 most Powerful Women' by Fortune India.

Currently, she serves as an Independent Director on the boards of Eternal Limited, Godrej Properties, Polycab India, JSW Cement, Axis Capital, Ideaforge Technology, Girnar Software (Car Dekho). She has been a Director on the board of Oxfam and represented Women's World Banking as their Nominee Director in India.

Ms. Sutapa is an Advanced Leadership Fellow (2015) at Harvard University and is a gold medalist in Economics from the XLRI School of Management in India, and an Economics major from Presidency College, Kolkata. She has served on the CII National Committee on 'Women's Empowerment' and 'The Indian Women Network', the CII National Committee on 'Integrity and Transparency in Governance' and the Advisory Panel of the 'India Responsible Business Forum'.

#### **Registered Office**

##### **Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

#### **Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

**CIN** : L24239AP2005PLC047518

**Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

*(Pursuant to SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)*

**Further Investment in KRKA Pharma Private Limited**

a	Name of the target entity, details in brief such as size, turnover etc.	KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is INR 370,00,00,000/- divided into 37,00,00,000 equity shares of INR 10/- each and paid-up Share Capital of the Company is INR 315,00,00,000/- divided into 31,50,00,000 equity shares of INR 10/- each.  Turnover: 2025-26 – INR 10.47 million
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Yes. KRKA is the joint venture of the Company having few common Directors. The proposed investment in KRKA by the Company would fall within the purview of related party transaction in terms of SEBI Listing Regulations. The nature of interest is to the extent of investment by the Company and the transaction is being done at arms' length basis. No Promoter/ Promoter Group/ other Group Company is holding equity shares or any interest in the target entity.
c	Industry to which the entity being acquired belongs	KRKA belongs to the pharmaceutical industry.
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	KRKA is already a joint venture company of our Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to meet its capex plan for setting up of a manufacturing facility.
e	Brief details of any governmental or regulatory approvals required for the acquisition	No approvals required.
f	Indicative time period for completion of the acquisition	The investment by the Company is expected to be completed during the financial year 2026-27.
g	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration by way of subscribing to Equity Shares which shall be issued by KRKA to the Company.
h	Cost of acquisition and/or the price at which the shares are acquired	Cost of acquisition: An amount of INR equivalent of Up to EURO 9,800,000/- (Euro Nine Million and Eight Hundred Thousand only) Price at which the shares are acquired: INR 10/- each per equity share (Face Value) on Rights Issue basis.
i	Percentage of shareholding / control acquired and / or number of shares acquired	The current percentage of shareholding in the target entity is 49% and after this investment by our Company and the co-venturer, the percentage of shareholding by the Company shall remain same at 49%.
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: KRKA was incorporated in April, 2024 and is yet to commence its business operations but however the Company is currently rendering R&D services. Date of Incorporation: April 12, 2024 Country in which the acquired entity has presence: India Turnover for the last three years: 2023-24 – Not Applicable 2024-25 – Nil 2025-26 – INR 10.47 million

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

**Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
(Pursuant to SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)

**Voluntary closure of Laurus Generics GmbH (LG GmbH), a step-down subsidiary of the Company**

a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	For the financial year ended March 31, 2026 (Amount in Euro)  Revenue of LG GmbH: Nil Networth of LG GmbH: (10,53,091)
b	Date on which the agreement for sale has been entered into	Not applicable, the Laurus Generics GmbH, Germany will be closed subject to regulatory approvals.
c	The expected date of completion of sale/disposal	As per the regulatory timelines applicable in Germany. The Company shall duly intimate the exchanges upon completion of the closure process.
d	Consideration received from such sale/disposal	Not applicable
e	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Not applicable
f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Laurus Generics GmbH is a step-down wholly owned subsidiary of the Company.
g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not applicable
h	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale	Not applicable

**Registered Office**

**Laurus Labs Limited**

Laurus Enclave, Plot Office 01, E, Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **F** +91 891 682 1103

**E** info@lauruslabs.com, **W** lauruslabs.com

**Corporate Office**

Plot No. 103, Road No 1, Jubilee Hills,  
Hyderabad, Telangana - 500 033, India.

**T** +91 40 6659 4333

**F** +91 40 6659 4320

**CIN** : L24239AP2005PLC047518